Validating Low-Dose Iohexol as a Marker for Glomerular Filtration Rate by In Vitro and In Vivo Studies.

ABSTRACT: Clearance of an intravenous iohexol dose of 3235 mg is used to assess glomerular filtration rate (GFR), although systematic assessment of its pharmacokinetic (PK) properties is incomplete. The objectives of the present investigations were (i) to assess potential interactions of iohexol with important drug transporters, and (ii) whether a 259 mg dose could replace the current standard dose. In vitro, we evaluated whether iohexol inhibits or is transported by renal transporters (hOAT1/3, hOCT2, and hMATE1/2K) or other transporters (hOATP1B1/3, hOCT1, and hMDR1) using cell-based and vesicle-based systems. In vivo, we conducted a clinical trial with 12 volunteers with the administration of single intravenous doses of 3235 mg ("reference") and 259 mg ("test") using a changeover design. Plasma a

SUBMITTER: Dong Q 

PROVIDER: S-EPMC11788587 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature